Pivalat de Flumetazon may be available in the countries listed below.
Flumetasone 21-pivalate (a derivative of Flumetasone) is reported as an ingredient of Pivalat de Flumetazon in the following countries:
International Drug Name Search
Enacor may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enacor in the following countries:
International Drug Name Search
Olfex Bucal may be available in the countries listed below.
Budesonide is reported as an ingredient of Olfex Bucal in the following countries:
International Drug Name Search
Isozid may be available in the countries listed below.
Isoniazid is reported as an ingredient of Isozid in the following countries:
International Drug Name Search
In the US, Doxercalciferol (doxercalciferol systemic) is a member of the drug class vitamins and is used to treat Secondary Hyperparathyroidism.
US matches:
Rec.INN
A11CC08
0054573-75-0
C28-H44-O2
412
Vitamin D analogue
(5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraene-1alpha,3beta-diol (WHO)
9,10-Secoergosta-5,7,10(19),22-tetraene-1,3-diol, (1-alpha,3-beta,5Z,7E,22E)-
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| WHO | World Health Organization |
Etoposide Fidia may be available in the countries listed below.
Etoposide is reported as an ingredient of Etoposide Fidia in the following countries:
International Drug Name Search
Analgan may be available in the countries listed below.
Paracetamol is reported as an ingredient of Analgan in the following countries:
International Drug Name Search
Ruvominox may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Ruvominox in the following countries:
International Drug Name Search
Naxin may be available in the countries listed below.
Naproxen is reported as an ingredient of Naxin in the following countries:
International Drug Name Search
Econazole Biogaran may be available in the countries listed below.
Econazole nitrate (a derivative of Econazole) is reported as an ingredient of Econazole Biogaran in the following countries:
International Drug Name Search
Paclitaxel Mayne may be available in the countries listed below.
Paclitaxel is reported as an ingredient of Paclitaxel Mayne in the following countries:
International Drug Name Search
1.1. Breast tissue revitalisation
1.2. Breast Firming.
2.1. Treatment for IM application: 1 vial 1-3 times a week according to severity and clinic evolution.
2.2. Treatment using mesotherapy technique: Apply 0,3 ml for each point. Using a 13 mm, 30G or a 4 mm, 27G needle, make the classic intradermal injections utilizing mesotherapy technique.
Sites of application: Tissue area around the breast, without injecting the mammal gland.
- From the clavicle, go down along the pectoral muscle with 3 parallel injection lines.
- From the areola, proceed with 4 injection lines, in a sunburst shape.
- In the space below the breast, along its insertion on the thorax.
Standard protocol consists of one treatment a week for 5-7 weeks. For prolonged treatments, 2 treatments for the first week, 1 treatment a week for 1 month and then 1 treatment a month are recommended.
Discard unused solution.
2.3. Opening of Vials: Use sterile needles and sterile syringe. Do not reuse. Do not use if foreign particles are present. Draw 1 cc of air into syringe, insert needle into vial inject air and withdraw the solution into the syringe.
3.1. Injectable solution for subcutaneneous, intradermal or intramuscular administration.
Pharmaceutical forms: 2 ml glass vials
3.2. Each ingredient is attenuated according to the procedures stated in the Homeopathic Pharmacopeia of United States.
Active ingredients: Adenosintriphosphate 10X; Cis-Aconitic acid 10X; Embryo 6X; Hypophysis 6X; Hypophysis 30X; Magnesia phosphorica 10X; Mamma 6X; Mamma 30X; Nadidum 10X; Old man in the spring 4X; Pulsatilla 4X; Skin tissue 6X; Uterus 6X.
Inactive ingredient: Sterile isotonic sodium chloride solution.
4.1. There is no history of hypersensitivity to OMEOFORMULA®4-BREAST. However patients with a known hypersensitivity to any ingredient should be tested before use. Make a spot injection (0.1ml) into the forearm and observe for any reactions for 1 hour.
5.1. Be sure to disinfect the area before application. Skin disinfection helps avoid the infection at the site of administration due to saprophytic bacteria (i.e. atypical mycobacteria, staphylococcus genus) that may be present on the skin.
6.1. The most common mild adverse reaction is slight reddening at the injection site due to the mechanical effect of the needle or a superficial skin reaction of mild erythema.
7.1. None Known.
8.1 Pregnancy: Pregnancy category C. Animal reproduction studies have not been conducted with OMEOFORMULA®4-BREAST. OMEOFORMULA®4-BREAST should not be administered to a pregnant woman.
8.2 Nursing mothers: OMEOFORMULA®4-BREAST is not indicated for use in a nursing woman.
8.3 Pediatric use: OMEOFORMULA®4-BREAST is not indicated for pediatric use.
8.4 Geriatric use: No restrictions.
9.1. No Known.
10.1. No Known.
OMEOFORMULA® 4-BREAST is a sterile solution made with isotonic sodium chloride solution.
Its formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred in Materia Medica.
The firming and toning activity is due to the suis-organ ingredients that are supported with the ingredients that stimulate the collagen pathway.
12.1. Mechanism of Action
The medication acts through a low-dose enzymatic mechanism.
12.2. Pharmacodynamics
The physiological effects of OMEOFORMULA® 4-BREAST is due to the effects of the ingredients, as they are listed in the Homeopathic Materia Medica.
12.3. Pharmacokinetics
The homeopathic attenuation provides complete bioavability of the active ingredients.
13.1. OMEOFORMULA® 4-BREAST has no level of toxicity due to the attenuation of the ingredients.
OMEOFORMULA®4-BREAST formulation is based on classical Homeopathy and each ingredient has been selected according to the homeopathic description as referred in Materia Medica.
15.1. E.Italia, M. De Bellis: Manuale di Omeo-mesoterapia – Guna Ed. 1995
15.2. H.H.Reckeweg: Materia Medica omeopatica. Ed. 1 Guna Editore.
17.1. Patients should be informed of the homeopathic approach and the therapeutic goals of OMEOFORMULA® 4-BREAST.
| OMEOFORMULA4-BREAST aconitic acid, cis - adenosine triphosphate - magnesium phosphate - nadide - pulsatilla vulgaris - senecio vulgaris - sus scrofa mamma - sus scrofa pituitary gland - sus scrofa skin - sus scrofa uterus - sus scrofa embryo - injection, solution | |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| unapproved homeopathic | 09/29/2006 | ||
| Labeler - Guna spa (430538264) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| Guna spa | 430538264 | manufacture | |
L-Thyroxin may be available in the countries listed below.
Levothyroxine sodium salt (a derivative of Levothyroxine) is reported as an ingredient of L-Thyroxin in the following countries:
International Drug Name Search
